Literature DB >> 23127882

Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.

Adam Gerstenecker1, Benjamin Mast, Kevin Duff, Tanis J Ferman, Irene Litvan.   

Abstract

Cognitive difficulties appear to be a more prevalent clinical feature in progressive supranuclear palsy (PSP) than previously thought, and significant cognitive impairment is prevalent in a majority of patients PSP patients not considered clinically demented. The neurocognitive performance of 200 patients with PSP across multiple sites was examined with a variety of commonly used neuropsychological tests. Results indicate primary executive dysfunction (e.g., 74% impaired on the Frontal Assessment Battery, 55% impaired on Initiation/Perseveration subscale of the Dementia Rating Scale), with milder difficulties in memory, construction, and naming. These results have important clinical implications for providers following patients with PSP.

Entities:  

Mesh:

Year:  2012        PMID: 23127882      PMCID: PMC3569947          DOI: 10.1093/arclin/acs098

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  35 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.

Authors:  Richard G Brown; Lucette Lacomblez; Bernard G Landwehrmeyer; Thomas Bak; Ingo Uttner; Bruno Dubois; Yves Agid; Albert Ludolph; Gilbert Bensimon; Christine Payan; Nigel P Leigh
Journal:  Brain       Date:  2010-06-24       Impact factor: 13.501

3.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

4.  Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy.

Authors:  P Soliveri; D Monza; D Paridi; F Carella; S Genitrini; D Testa; F Girotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

5.  Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease.

Authors:  D Aarsland; I Litvan; D Salmon; D Galasko; T Wentzel-Larsen; J P Larsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

6.  Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  E R Maher; E M Smith; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

7.  Decisional capacity for research participation in individuals with mild cognitive impairment.

Authors:  Angela L Jefferson; Susan Lambe; David J Moser; Laura K Byerly; Al Ozonoff; Jason H Karlawish
Journal:  J Am Geriatr Soc       Date:  2008-05-12       Impact factor: 5.562

8.  Cognitive deficits in Huntington's disease on the Repeatable Battery for the Assessment of Neuropsychological Status.

Authors:  Kevin Duff; Leigh J Beglinger; Danielle Theriault; Jessica Allison; Jane S Paulsen
Journal:  J Clin Exp Neuropsychol       Date:  2009-05-29       Impact factor: 2.475

9.  Memory impairment in patients with progressive supranuclear palsy.

Authors:  I Litvan; J Grafman; C Gomez; T N Chase
Journal:  Arch Neurol       Date:  1989-07

10.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

View more
  26 in total

1.  Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsy.

Authors:  Kevin Duff; Christopher Randolph; Adam L Boxer
Journal:  Clin Neuropsychol       Date:  2019-09-27       Impact factor: 3.535

2.  Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status.

Authors:  Kevin Duff; Dana McDermott; Dan Luong; Christopher Randolph; Adam L Boxer
Journal:  J Clin Exp Neuropsychol       Date:  2019-02-04       Impact factor: 2.475

Review 3.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

4.  MRI gray and white matter measures in progressive supranuclear palsy and corticobasal syndrome.

Authors:  Neeraj Upadhyay; Antonio Suppa; Maria Cristina Piattella; Matteo Bologna; Flavio Di Stasio; Alessandra Formica; Francesca Tona; Carlo Colosimo; Alfredo Berardelli; Patrizia Pantano
Journal:  J Neurol       Date:  2016-07-13       Impact factor: 4.849

5.  Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

Authors:  Jee Bang; Iryna V Lobach; Anthony E Lang; Murray Grossman; David S Knopman; Bruce L Miller; Lon S Schneider; Rachelle S Doody; Andrew Lees; Michael Gold; Bruce H Morimoto; Adam L Boxer
Journal:  Parkinsonism Relat Disord       Date:  2016-04-18       Impact factor: 4.891

6.  Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Authors:  Irene Litvan; Peter S J Lees; Christopher R Cunningham; Shesh N Rai; Alexander C Cambon; David G Standaert; Connie Marras; Jorge Juncos; David Riley; Stephen Reich; Deborah Hall; Benzi Kluger; Yvette Bordelon; David R Shprecher
Journal:  Mov Disord       Date:  2016-02-08       Impact factor: 10.338

7.  The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage.

Authors:  Han Soo Yoo; Seok Jong Chung; Soo-Jong Kim; Jung Su Oh; Jae Seung Kim; Byoung Seok Ye; Young Ho Sohn; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-04       Impact factor: 9.236

Review 8.  Parkinsonian syndromes.

Authors:  David R Williams; Irene Litvan
Journal:  Continuum (Minneap Minn)       Date:  2013-10

9.  NIH EXAMINER: conceptualization and development of an executive function battery.

Authors:  Joel H Kramer; Dan Mungas; Katherine L Possin; Katherine P Rankin; Adam L Boxer; Howard J Rosen; Alan Bostrom; Lena Sinha; Ashley Berhel; Mary Widmeyer
Journal:  J Int Neuropsychol Soc       Date:  2013-10-08       Impact factor: 2.892

10.  Genetic influences on cognition in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Erik D Roberson; Gerard D Schellenberg; David G Standaert; David R Shprecher; Benzi M Kluger; Irene Litvan
Journal:  Mov Disord       Date:  2017-10-27       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.